Posted by Michael Wonder on 22 Feb 2022
Celltrion's auto-immune disease biosimilar wins further approval in Europe
22 February 2022 - South Korean pharmaceutical giant Celltrion said Tuesday that a high concentration version of its auto-immune disease biosimilar Yuflyma has won approval from European drug authorities.
The EMA gave the green light to Celltrion's application to sell Yuflyma -- a biosimilar referencing blockbuster drug Humira by AbbVie.
